The Federal Drug Administration (FDA) has approved the expansion of an old drug’s use as a treatment for some individuals with autism, generating widespread interest and market activity. This endorsement has led to a surge in demand for over-the-counter supplements containing the same ingredients, with some consumers rushing to purchase them.
Dr. Marty Makary, the FDA commissioner, addressed the issue at the White House on Monday, where President Trump led a briefing with his top health officials, including Health Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, the head of the Medicare agency. During the session, Trump pledged to study the root causes of autism, emphasizing the need for further research and potential policy changes.
The decision has sparked discussions about the evolving landscape of autism treatment and the FDA’s role in approving medications for rare conditions. Experts suggest that this development may influence future regulatory decisions and could lead to more research into alternative therapies for autism.